The Ultimate Guide to Functional Gut Symptoms: Beyond IBS
Most people who live with ongoing gut symptoms — the bloating that swells as the day wears on, the pain that flares after meals, the bowel habit that never quite settles into a rhythm — do not fit the strict clinical definition of irritable bowel syndrome. If that describes you, or the patient sitting across from you, it is not a diagnostic failure. It is arguably the single most important fact in this whole conversation.
For decades, "IBS" has been the catch-all we reach for when the bowel misbehaves and the scans come back clear. Yet the numbers tell a surprising story. Under the current, tighter Rome IV research criteria, strict IBS accounts for only about four percent of adults2, while more than forty percent of adults worldwide meet criteria for at least one disorder of gut–brain interaction1. The gap between those two figures is not empty. It is filled with real people who have real, often debilitating symptoms — and no tidy label.
When a symptomatic patient does not tick the IBS boxes, that is expected, not a mystery. The practical shift — and it is the shift this entire article is built around — is to stop asking "Is this IBS?" and start asking "Which driver is doing the most damage here?"
Disorder of gut–brain interaction (DGBI) is the modern umbrella term (introduced by the Rome IV framework) for conditions like IBS. It is defined by a characteristic pattern of symptoms in the absence of alarm features or organic disease. Crucially, "functional" does not mean "in your head" or "nothing is wrong" — it names a genuine problem in how the gut and brain communicate, which is real and treatable.
Section 1
A label names the problem; a driver tells you what to do
Think about fever for a moment. A fever is not a diagnosis — it is a sign with many possible causes, and you treat the infection, not the thermometer reading. "IBS" and "bloating" behave in exactly the same way. They describe what is happening, but not why, and different causes need genuinely different treatments.
This matters because DGBI are defined by description and exclusion — by what the symptoms look like and what serious diseases have been ruled out — rather than by a single, tractable mechanism you can aim at. A definition built on "what it is not" cannot, by itself, tell you what to do next. That is why symptom-directed management of IBS so often proceeds by trial and error, and why two people with identical symptoms can need opposite strategies.
To make this workable, it helps to group the underlying drivers into three broad, overlapping domains. Think of them not as boxes to sort patients into, but as a lens for working out where the trouble is concentrated.
The gut–brain connection
How the gut and nervous system talk to each other — including a gut that registers normal sensations as painful.
The intestinal barrier
The gut lining that decides what gets through — a regulated gate that can be pushed open too readily.
The microbiome
The community of gut microbes — which can be disrupted by infection or antibiotics and slow to recover.
Be honest about what this model is. There is no validated test for a "three-domain" classification; the domains are not mutually exclusive, and most patients have some of all three at once. Its value is that it makes clinical reasoning explicit and testable. Use it to decide which driver to target first — not to "diagnose a domain."
Section 2
Domain one — the gut–brain connection
For a great many people with functional gut symptoms, the problem is not more gas, faster transit or some structural fault. It is a gut that hurts in response to entirely normal stimuli. This phenomenon, called visceral hypersensitivity, is detectable in up to around sixty percent of people with IBS and sits at the heart of abdominal pain4.
The best analogy is sunburn. After a day in the sun, an ordinary touch on your shoulder becomes painful — not because the touch changed, but because the sensor is turned up. In much of IBS the stimulus is normal; the volume is turned up.
What turns the volume up? Increasingly, we can point to specific machinery. In the gut lining of people with IBS, immune cells called mast cells sit close to sensory nerves, releasing histamine, tryptase and other mediators that activate those nerves — and their density tracks with the frequency and severity of pain4. Increased release of serotonin from the gut lining follows the same pattern5. The lining, its immune cells and its nerves are not separate systems; they are one interconnected circuit6.
This circuit is the mechanistic bridge between our first two domains. It explains why a barrier-directed intervention can plausibly reduce pain, and why a histamine-aware approach is reasonable when pain, food-reactivity and barrier signs cluster together in the same person.
This immune activation is low-grade and neuroimmune — it sits below the threshold of routine inflammatory markers. A normal CRP or faecal calprotectin does not exclude a mast-cell-and-nerve mechanism. When pain dominates and tracks with meals and stress more than with stool form, think visceral hypersensitivity, and consider histamine and mast-cell pathways rather than reaching first for motility agents.
A word of caution is owed here, because this is the field's biggest over-reach. You will have seen headlines claiming your microbiome controls your mood. In animals, altered gut microbes genuinely can change behaviour. In humans, that causal claim is largely unproven — robust causal microbiome evidence is confined to a handful of conditions such as Helicobacter pylori in peptic ulcer and Clostridioides difficile infection, while most gut–brain-mood claims rest on association7. You may well treat the gut and see mood lift — that is worth pursuing — but it is an exciting hypothesis, not yet a promise we can make to patients.
Section 3
Domain two — the intestinal barrier
Few phrases in gut health are as loved and as misunderstood as "leaky gut." So let us start by drawing the barrier correctly. The gut lining is not a passive wall that springs holes. It is a single layer of cells sealed together by tight junctions — dynamic protein complexes that open and close on purpose, moment to moment, under active control8.
The barrier is a drawbridge, not a torn net. Permeability rises and falls physiologically — it even loosens a little after meals. When the timing or degree of that opening becomes dysregulated, we can influence it. That single reframe disciplines everything that follows.
"Leaky gut" is a mechanism you explain, not a diagnosis you treat. Increased intestinal permeability is a real, measurable change associated with many conditions — but it is not a stand-alone disease with its own criteria. Treating it as a diagnosis inverts cause and effect. The clinical move is to find and treat what is driving the barrier change, using barrier support as an adjunct.
So what actually drives the barrier open? The most useful way to organise the culprits is by how modifiable they are — because that is what turns a messy risk-factor list into a plan. A systematic review of risk factors for increased permeability in adults identified a Western-style dietary pattern, along with metabolic markers such as raised blood lipids, high blood sugar and insulin resistance, among the strongest associations11. Alcohol and non-steroidal anti-inflammatory drugs (NSAIDs) are well-established barrier disruptors, and dysbiosis both drives and results from barrier change.
Here is the part that runs against popular wisdom: diet, alcohol and NSAIDs move the barrier more than stress does. Psychological stress is a genuine influence, but its human effect sizes are smaller and less consistent than the attention it receives. The highest-leverage interventions are, frankly, the unglamorous ones — capping alcohol within national guidelines, minimising NSAIDs where possible, and shifting away from a Western dietary pattern — long before any proprietary supplement enters the picture.
Do not order a serum zonulin test to diagnose barrier dysfunction or to prove a treatment worked. The widely used commercial ELISA fails specificity testing — it does not reliably detect the protein it claims to, binding others such as properdin instead9 — and its results do not correlate with the functional dual-sugar reference test10. If a functional readout genuinely matters (research, or a refractory case), a lactulose:mannitol dual-sugar test is the more valid measure10; otherwise, treat the drivers and judge the response clinically.
A loosened barrier plausibly matters for the whole body, not just the gut. In mice, a high-fat diet raises circulating bacterial lipopolysaccharide (LPS, or "endotoxin") two- to three-fold — a phenomenon dubbed metabolic endotoxaemia — and infusing LPS reproduces weight gain and insulin resistance14. In humans this remains an association rather than proven cause, so it is best presented as a compelling, human-plausible mechanism — a good reason that diet matters — not as a promise that we can measure and reverse endotoxaemia.
It is worth noting that the first evidence-graded clinical practice guideline for assessing and managing increased intestinal permeability came out of this work13, built on systematic reviews of disease associations12 and risk factors11. Like all good guidelines, it is a solid anchor and a living document — the position on zonulin has only hardened since, and newer drivers such as dietary emulsifiers continue to be characterised.
Section 4
Domain three — infection, dysbiosis and recovery
If you want the cleanest proof that an event — not a personality or a character flaw — can drive gut symptoms, look at what happens after a gut infection. A meta-analysis of 45 studies found that a bout of infectious gastroenteritis raises the subsequent risk of IBS roughly four-fold15. And the pathogen matters: post-infection IBS is most common after parasitic infection, then bacterial — around one in five people after Campylobacter — then viral16.
The clinical lesson is simple: always take an infection history. Recent gastroenteritis reframes a "new IBS" as a post-infectious, potentially recovering process — which changes the whole conversation from "you have a lifelong condition" to "let us support your recovery."
The over-called test
Small intestinal bacterial overgrowth (SIBO) is real, and it is more common in IBS than in healthy controls. But the popular breath test dramatically over-calls it. In a meta-analysis, SIBO was found in 35.5% of IBS patients by breath test versus only 13.9% by the more accurate jejunal aspirate culture — nearly three times the culture-based rate17.
Interpret a breath test in clinical context — symptoms, risk factors, transit — and prefer the more conservative positivity criteria; the standard has been applied inconsistently, with case-control studies using many different methods18. Above all, resist the retest-and-retreat cycle: do not launch repeated courses of antimicrobials on breath-test numbers alone.
This also reframes so-called "food intolerance." Often it isn't the food — it's what your microbes do with it. When fermentable food meets an overpopulated or mislocated small-bowel microbiota, gas and osmotic load rise soon after eating, producing the bloating and pain that patients naturally attribute to that food. Fix the fermentation context, and most foods can usually come back. (Genuine immune or enzyme-mediated intolerances — coeliac disease, lactase deficiency — are real and stay firmly on the list to exclude.)
Recovery is real — but not complete, and not on your schedule
Here is one of the most quietly important findings in gut medicine. When healthy volunteers were given a strong four-day course of broad-spectrum antibiotics, their gut microbiota was driven close to collapse and then recovered most of the way back over about six weeks. Yet at six months, nine common commensal species that had been present beforehand were still undetectable, and the disruption had transiently enriched antibiotic-resistance genes during recovery19.
The honest reading sits between the scare and the shrug. This does not mean antibiotics "wreck the gut permanently" — the headline is resilience, with a small lasting footprint, in a deliberately extreme experiment. Nor does it justify the false reassurance that everything simply bounces back. The truth is person-specific: assume more disruption after repeated or prolonged courses, in older people, and where baseline diversity is low; assume good recovery after a single short course in a healthy person; and support recovery where the risk profile warrants it.
Do not assume a patient's microbiome has "fully recovered" after antibiotics just because their symptoms settled. There is a genuine window in which active support — dietary diversity, fermented foods, targeted strains and time — is rational, alongside a standing case for antibiotic stewardship. Every unnecessary antimicrobial course, botanical ones included, also selects for resistance genes in that person's own gut19.
Put the threads together and a recognisable patient emerges: someone caught in cycle after cycle of removal — antimicrobials for an over-called "SIBO," another elimination diet — who remains unwell. The patient stuck on endless removal usually needs the opposite: rebuilding. Which brings us to what actually works.
Section 5
Matching the tool to the driver
This is where precision earns its keep. And precision matters here more than almost anywhere else in medicine, for one sobering reason: the pooled placebo response in IBS trials is 37.5%20 — and it is essentially the same in complementary-medicine trials as in conventional ones, driven by the length of treatment and the number of appointments rather than the remedy itself21. When nearly four in ten people improve on a dummy treatment, anything less than precise is indistinguishable from a well-delivered ritual.
Nowhere is this clearer than with probiotics. A probiotic is not a probiotic — the strain is the drug. Genus and species tell you almost nothing; effects are strain-specific, and each strain must be judged on its own trials. Different strains produce different effects for the very same indication.
If you cannot name the strain and cite its trial, you are not prescribing a probiotic — you are prescribing hope. Prescribe by strain and dose, matched to the driver and the outcome you want, and record it as you would any medicine.
The table below summarises the interventions with the strongest signals for the drivers in this article, graded honestly. A note on transparency: several of the named-strain trials are single, industry-funded studies conducted specifically in diarrhoea-predominant IBS (IBS-D). Applying them to the broader beyond-IBS patient is a reasoned extrapolation — the shared drivers are mechanism-level — but it is not the same as having trials in that exact population, and it is only right to say so.
| Intervention | Best-matched use | Key evidence | Grade | How firmly |
|---|---|---|---|---|
| Glutamine (5 g, 3×/day) | Post-infectious IBS-D with measured increased permeability | RCT (n=115): large responder benefit + reduced permeability29 | B | Advocate |
| L. plantarum Lpla33 | Diarrhoea & urgency (IBS-D type) | Dose-ranging RCT (n=307): significant symptom reduction25 | B | Advocate |
| B. longum ES1 (live) | IBS-D with barrier/sensitivity features | 3-arm RCT (n=200): clinically meaningful symptom reduction26 | B | Advocate |
| HT-ES1 (heat-treated) | Symptomatic IBS-D where a non-live form is preferred | Effective in IBS-D26; near-null in healthy adults27 | B | Advocate / Flag |
| L. rhamnosus GG | Preventing antibiotic-associated diarrhoea | Meta-analysis: RR ≈ 0.3122,23 | A | Assert |
| S. boulardii | Preventing antibiotic-associated diarrhoea (+ C. difficile) | Meta-analysis: RR ≈ 0.3722,24 | A | Assert |
| Routine multi-strain probiotic | Restoring the microbiome after antibiotics | Landmark study: can delay recovery32 | C | Challenge |
| Botanical antimicrobials | SIBO only when genuinely confirmed | Retrospective: 46% vs rifaximin 34% (n.s.)34 | C | Offer / Flag |
Grade key: A consistent meta-analytic/RCT evidence · B one adequately powered RCT · C small, surrogate or indirect human evidence · D mechanistic/reasoning.
Glutamine: the whole idea in one trial
If a single study captures the thesis of this article, it is this one. In a randomised, placebo-controlled trial, adults were enrolled only if they met three conditions: a gut infection at least a year earlier, current diarrhoea-predominant symptoms, and objectively measured increased intestinal permeability. They received oral glutamine (5 g three times daily) or placebo for eight weeks. The proportion who responded was dramatically higher with glutamine than placebo — an unusually large effect for any IBS intervention29.
The effect was large because they chose the right patients — post-infectious onset plus a measured barrier defect. That is the entire lesson of this article in one trial: define the driver, then match the agent. Give glutamine to that specific phenotype and you have a rational, low-risk trial with a real evidence signal; give it to every IBS patient and you dilute the very targeting that produced the result.
Glutamine leads the barrier-nutrient shelf; the rest are reasonable adjuncts, not the plan. Zinc carnosine (particularly with bovine colostrum) has blunted exercise-induced permeability spikes in a small crossover study30, and oral zinc has induced tight-junction remodelling in human intestine31 — useful second-tier options, but their effects are on markers rather than proven symptom relief. Vitamin D repletion is sensible general practice, and prebiotics and polyphenols act indirectly, as dietary rather than pharmacological levers.
The rise of the "dead" probiotic
One of the most intriguing developments in the field is the paraprobiotic — and it is not a marketing dodge. In that same three-arm IBS-D trial, a heat-treated, non-living version of the strain (HT-ES1) reduced symptoms about as much as the live form26.
A postbiotic (the older term is "paraprobiotic") is formally defined by the International Scientific Association for Probiotics and Prebiotics as a "preparation of inanimate microorganisms and/or their components that confers a health benefit on the host"28. The category is deliberately bounded — it requires a defined preparation and a demonstrated benefit, not merely dead cells. Judge a postbiotic by the same standard as a live probiotic: does this exact preparation have evidence?
Fun fact: that heat-treated strain eased symptoms in people with IBS-D, but did almost nothing in a separate pilot of people who were basically well27. Sometimes "dead" works — and sometimes a healthy gut simply has nothing to fix. That contrast is the whole philosophy in miniature: these tools help when matched to a genuine driver, and underwhelm when handed to a gut that does not need them.
Non-viability can even be a feature rather than a compromise. A preparation that cannot colonise cannot compete with your resident community during a vulnerable window — which matters more than you might expect, given what comes next.
The twist: probiotics can delay the recovery you want
We tend to assume that taking a probiotic after antibiotics can only help. In a landmark study, participants given broad-spectrum antibiotics then received either an eleven-strain probiotic, their own stored pre-antibiotic stool, or nothing at all. Compared with simply waiting, the probiotic caused a markedly delayed and incomplete return of the person's own indigenous microbiome — while restoring their own stored sample worked fastest, and watchful waiting outperformed the probiotic32.
Separate the two goals. To reduce the symptom of antibiotic-associated diarrhoea, an evidenced strain such as S. boulardii or LGG is reasonable22. But if the goal is restoring the indigenous microbiome after antibiotics, do not assume a generic probiotic helps — dietary diversity, time and strain-specific choices are the rational levers, and this is a setting where a non-viable option is worth considering. (The picture is strain-specific: one fermented-milk study did show a small benefit33.)
Botanicals and the two-hour myth
Botanical antimicrobials deserve an honest hearing. In one retrospective series, a herbal protocol cleared SIBO about as often as the antibiotic rifaximin (46% versus 34%) with fewer side effects — though the difference was not statistically significant and the study design was weak34. That makes them a fair, gentler option when antimicrobial treatment is genuinely indicated — not a licence for repeated cycling, because every antimicrobial course, herbal or pharmaceutical, feeds the resistome, and relapse usually reflects an unaddressed driver rather than a failed drug.
And that popular rule about spacing your probiotic two hours from your antibiotic? It is folklore with little outcome evidence behind it. What actually matters is whether that strain survives that antibiotic — S. boulardii is a yeast and is intrinsically resistant to antibacterial antibiotics, so it can be taken alongside them, whereas some bacterial strains are inactivated by penicillins. Stop timing the gap; ask whether the strain survives the antibiotic, and whether a live organism belongs there at all.
Section 6
Putting it together: sequence, not shotgun
With the tools in hand, the question becomes one of order. A useful sequence — offered as reasoning made visible, not a rigid protocol — is repair, then relieve or remove, then rebuild.
Repair
Reduce the drivers — alcohol, NSAIDs, a Western dietary pattern — and support the barrier where the phenotype fits.
Relieve / Remove
Ease symptoms, and clear a genuinely confirmed overgrowth or pathogen — not an over-called breath test.
Rebuild
Restore microbial diversity and barrier resilience with dietary variety, targeted strains and time.
The entry point depends on the dominant driver — this is a decision order you can defend and change, not a recipe to obey.
Whatever the order, one discipline protects you from being fooled: change one thing at a time when you can. With a placebo response near 40%20, starting five interventions together means that if the patient improves, you will never know which one worked — or whether any was active at all. Staggering preserves attribution. When someone is suffering and you must combine, do so deliberately, and say out loud that you have traded certainty for speed.
To see why the driver — not the label — must direct the plan, consider two patients who look, on paper, identical.
Case Study · The Two-Patient Problem
Same symptoms, opposite drivers, opposite plans
Both patients are fictional, de-identified composites created for illustration.
Patient A — "Maya", 34
Post-meal pain, bloating and urgency that don't quite meet Rome IV IBS. Normal coeliac serology and calprotectin. A bout of gastroenteritis eight months ago. She attributes her symptoms to specific foods.
Phase 1 — Repair first
- Reduce alcohol and NSAIDs; address the fermentation context rather than eliminate foods endlessly
- Given the post-infectious, barrier picture, trial glutamine (ideally with a measured permeability result)
- Be histamine-aware for the pain component
- Add a barrier/sensitivity strain (ES1 or HT-ES1) as an adjunct
At 8-week review
Patient B — "David", 41
Bloating and irregular bowel habit dating from repeated antibiotic courses six months ago. Already through several rounds of "SIBO" treatment on the strength of a breath test, without lasting benefit.
Phase 1 — Rebuild first
- Stop removing; start rebuilding with dietary diversity, fermented foods and time
- Strain-specific choices rather than a generic probiotic — mindful that routine probiotics can delay indigenous recovery
- Consider a non-viable preparation or a food-first approach
- Explicitly decline to re-treat an over-called breath test
At 3-month review
There is, of course, a third patient — the one in whom removal genuinely comes first. When a pathogen or a real overgrowth is confirmed (not an isolated positive breath test), a targeted, time-limited antimicrobial is exactly right, followed by repair and rebuild. That scenario is precisely why antimicrobials are the wrong instinct for the first two.
Decide the review date before you start. Pre-specify a baseline symptom score and a realistic window per intervention — roughly 8 weeks for glutamine29, 8–12 weeks for named strains25, and 3–6 months for microbiome rebuilding, which is slower. Continue only on a meaningful, above-placebo change; otherwise stop and reassess the dominant driver. A planned review stops a 40% placebo response from writing the story for you.
The takeaways
Six shifts that change how you treat the gut
If you remember nothing else, remember that the driver — not the label — directs the plan; the strain — not the genus — is the medicine; and the sequence — not the shotgun — is the method. These six shifts capture the whole approach.
From label to driver
Stop chasing "IBS"; identify and treat the dominant driver.
From genus to strain
The specific strain at a specific dose is the intervention.
From "leaky gut" to barrier dysfunction
A modifiable mechanism to support, not a diagnosis to cure.
From passive to active recovery
Actively support the microbiome after infection or antibiotics.
From "dead probiotics" to a real class
Postbiotics are a defined, legitimate therapeutic category.
From simultaneous to sequenced
Stagger interventions so you know what actually worked.
None of this points to a single magic bullet. The multimodal reality of gut health is that diet, the microbiome, the gut–brain connection and lifestyle all have to be addressed together — no one intervention is a cure. Precision is not fastidiousness. It is the only thing that separates genuine treatment from a well-delivered ritual.
Further Your Practitioner Education — Free Webinar
Are you a practitioner who wants to take this further? Everything above comes from a much bigger clinical conversation — and Dr Brad Leech is unpacking all of it in a free practitioner webinar with BioPractica, Beyond IBS: Uncovering the Drivers of Functional Gut Symptoms and Dysbiosis. The session goes deeper into the three overlapping domains of gut dysfunction, the evidence for live probiotics versus heat-treated paraprobiotics, how to protect and rebuild the microbiome through antibiotic and antimicrobial treatment, and a practical, sequenced "repair, relieve and remove, rebuild" framework worked through three real clinical scenarios. Join live on Wednesday 30 September at 6:00 pm AEST — secure your free place at BioPractica.
Dr Brad Leech
Brad is a PhD-qualified Clinical Nutritionist and Herbalist specialising in chronic autoimmune conditions and complex gastrointestinal disorders. He provides complete and personalised care to his patients using functional nutrition, integrative medicine and holistic wellness.